Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD

Y. Inamoto; M. Jagasia; W. A. Wood; J. Pidala; J. Palmer; N. Khera; D. Weisdorf; P. A. Carpenter; M. E D Flowers; D. Jacobsohn; P. J. Martin; S. J. Lee; S. Z. Pavletic

doi:10.1038/bmt.2013.225

Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD

Y. Inamoto, M. Jagasia, W. A. Wood, J. Pidala, J. Palmer, N. Khera, D. Weisdorf, P. A. Carpenter, M. E D Flowers, D. Jacobsohn, P. J. Martin, S. J. Lee, S. Z. Pavletic

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations: two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.

Original language	English (US)
Pages (from-to)	532-538
Number of pages	7
Journal	Bone marrow transplantation
Volume	49
Issue number	4
DOIs	https://doi.org/10.1038/bmt.2013.225
State	Published - Apr 2014

Bibliographical note

Funding Information:
We thank all participants in the web survey for their valuable time and opinions. This work was supported by grants CA118953 and CA163438 from the National Institutes of Health (NIH). The Chronic GVHD Consortium (U54 CA163438) is a part of the NIH Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Cancer Institute, and the Fred Hutchinson Cancer Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords

Allogeneic hematopoietic cell transplantation
Chronic GVHD
Consensus
Controversy
National Institutes of Health

Publisher link

10.1038/bmt.2013.225

Find It

Find It at U of M Libraries

Cite this

@article{641da199f81a4ec980af0f8c7c3a8bac,

title = "Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD",

abstract = "The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations: two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.",

keywords = "Allogeneic hematopoietic cell transplantation, Chronic GVHD, Consensus, Controversy, National Institutes of Health",

author = "Y. Inamoto and M. Jagasia and Wood, {W. A.} and J. Pidala and J. Palmer and N. Khera and D. Weisdorf and Carpenter, {P. A.} and Flowers, {M. E D} and D. Jacobsohn and Martin, {P. J.} and Lee, {S. J.} and Pavletic, {S. Z.}",

note = "Funding Information: We thank all participants in the web survey for their valuable time and opinions. This work was supported by grants CA118953 and CA163438 from the National Institutes of Health (NIH). The Chronic GVHD Consortium (U54 CA163438) is a part of the NIH Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Cancer Institute, and the Fred Hutchinson Cancer Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2014",

month = apr,

doi = "10.1038/bmt.2013.225",

language = "English (US)",

volume = "49",

pages = "532--538",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD

AU - Inamoto, Y.

AU - Jagasia, M.

AU - Wood, W. A.

AU - Pidala, J.

AU - Palmer, J.

AU - Khera, N.

AU - Weisdorf, D.

AU - Carpenter, P. A.

AU - Flowers, M. E D

AU - Jacobsohn, D.

AU - Martin, P. J.

AU - Lee, S. J.

AU - Pavletic, S. Z.

N1 - Funding Information: We thank all participants in the web survey for their valuable time and opinions. This work was supported by grants CA118953 and CA163438 from the National Institutes of Health (NIH). The Chronic GVHD Consortium (U54 CA163438) is a part of the NIH Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Cancer Institute, and the Fred Hutchinson Cancer Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2014/4

Y1 - 2014/4

N2 - The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations: two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.

AB - The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations: two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.

KW - Allogeneic hematopoietic cell transplantation

KW - Chronic GVHD

KW - Consensus

KW - Controversy

KW - National Institutes of Health

UR - http://www.scopus.com/inward/record.url?scp=84897490025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897490025&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.225

DO - 10.1038/bmt.2013.225

M3 - Article

C2 - 24464142

AN - SCOPUS:84897490025

SN - 0268-3369

VL - 49

SP - 532

EP - 538

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 4

ER -

Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this